Abstract
The cure for thalassemia involves correcting the genetic defect in a hematopoietic stem cell that results in reduced or absent β-globin synthesis and an excess of α-globin dimers. [...]
Highlights
Pediatric Oncology and Hematology Lalla Seràgnoli Unit, University of Bologna, Bologna, Italy have not achieved over these two decades a significant better EFS after a wide use of autologous hematopoietic n stem cell transplantation (HSCT), being the 5-year EFS respectively of 51%7 and 20%
New concepts of allogeneic HSCT and in ia particular HLA-mismatched HSCT for high risk solid tumors do not rely on escalation of c chemotherapy intensity and tumor load reducr tion but rather on a graft-versus-tumor effect. e We here report an experimental study design of HLA-mismatched HSCT for the treatment of m pediatric solid tumors and the inherent preliminary results
Primary neuroblastoma cells may lack high-level expression of MHC class 1 and class 2 antigens, they should still be good target cells for a cellular immune response given that there is upregulation of both classes of MHC molecules after conventional therapy and after exposure to proinflammatory cytokines
Summary
HLA-mismatched hematopoietic stem cell tranplantation for pediatric solid tumors are paradigmatic. High risk ESFT and RMS as well, Key words: HLA-mismatched hematopoietic stem cell tranplantation, childhood, solid tumors.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
